Medpace Holdings, Inc. provides clinical research-based drug and medical device development services in North America, Europe, and Asia. The company is headquartered in Cincinnati, Ohio.
| Revenue (TTM) | $2.84B |
| Gross Profit (TTM) | $2.05B |
| EBITDA | $634.46M |
| Operating Margin | 23.10% |
| Return on Equity | 117.90% |
| Return on Assets | 18.70% |
| Revenue/Share (TTM) | $100.62 |
| Book Value | $20.92 |
| Price-to-Book | 30.39 |
| Price-to-Sales (TTM) | 6.26 |
| EV/Revenue | 6.07 |
| EV/EBITDA | 27.14 |
| Quarterly Earnings Growth (YoY) | 25.40% |
| Quarterly Revenue Growth (YoY) | 8.50% |
| Shares Outstanding | $27.97M |
| Float | $22.73M |
| % Insiders | 18.66% |
| % Institutions | 90.02% |
Volatility is currently expanding
The Madison Mid Cap Fund (Class I) returned -2.09% in the third quarter, compared to the Russell Midcap Index return of -3.00%. The top five contributors for the quarter were Gartner, Medpace Holdings, Ross Stores, Revvity, and Waters Corporation. The bottom five detractors for the quarter were MKS, Floor & Decor Holdings, Carlisle Companies, Moelis and Co., and Glacier Bancorp.
Investors interested in stocks from the Medical Services sector have probably already heard of Concentra Group (CON) and Medpace (MEDP). But which of these two stocks presents investors with the better value opportunity right now?
Does Medpace (MEDP) have what it takes to be a top stock pick for momentum investors? Let's find out.
Medpace (MEDP) is at a 52-week high, but can investors hope for more gains in the future? We take a look at the company's fundamentals for clues.
Medpace (MEDP) possesses solid growth attributes, which could help it handily outperform the market.
Medpace (MEDP) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
Net new business awards reached $873 million in the third quarter. Ending backlog reached $3.2 billion, up 5.6% year over year.
Medpace Holdings, Inc. ( MEDP ) Q3 2026 Earnings Call October 22, 2026 9:00 AM EDT Company Participants David Ruhe - Associate Director of Financial Planning & Analysis August Troendle - CEO, President & Chairman Kevin Brady - CFO & Treasurer Conference Call Participants Michael Cherny - Leerink Partners LLC, Research Division Jailendra Singh - Truist Securities, Inc., Research Division Tucker Remmers - UBS Investment Bank, Research Division Ann Hynes - Mizuho Securities USA LLC, Research Division Justin Bowers - Deutsche Bank AG, Research Division Ryan Halsted - RBC Capital Markets, Research Division David Windley - Jefferies LLC, Research Division Christine Rains - William Blair & Company L.L.C., Research Division Eric Coldwell - Robert W.
Medpace NASDAQ: MEDP reported third-quarter 2026 revenue growth of 8.5% and record net new business awards, while management said the clinical research organization continues to see a strong operating environment marked by healthy request-for-proposal activity, initial award notifications and win rates.
Tiblio connects your broker and runs your put-and-call-writing strategy for you — on MEDP and any ticker you trade — then tracks every position and per-strategy win rate.
